Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of ToleroMune Grass in Grass Allergy
NCT01166061Phase 2Completed
- Sponsor
- NIOX Group
- Start
- Jul 2010
- Primary completion
- Apr 2011
- Modality
- Peptides, Peptide-based Cancer Vaccines, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of grass-spire in allergic rhinitis due to grass pollen (5 cohorts), sponsored by NIOX Group. Primary endpoint: Safety and tolerability of multiple intradermal injections up to 22 weeks. Started Jul 2010; status: completed.
02
Drugs
grass-spire
03
Conditions
allergic rhinitis due to grass pollen
Beyond the preview
Go deeper on NCT01166061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01166061.